Key result
Anti-phosphorylcholine antibody preserves coronary flow reserve and reduces vascular inflammation in atherosclerotic mice.
Answers are grounded in this paper and cite their sources.
This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.
No takes yet. Share an insight, caveat, or question.
Ståhle et al. (2020) studied Atherosclerosis. Therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids was evaluated on Coronary flow reserve and vascular 18F-fluorodeoxyglucose (18F-FDG) uptake. A therapeutic monoclonal IgG1 antibody against phosphorylcholine preserved coronary flow reserve and attenuated vascular 18F-FDG uptake in atherosclerotic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: